Search
Batroxobin
go.drugbank.com/drugs/DB09005InvestigationalIn addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. … Recombinant Batroxobin in relatively affordable and could be accessed by mass production.
Abarelix
go.drugbank.com/drugs/DB00106ApprovedWithdrawnPraecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Human growth hormone-releasing peptide 3
go.drugbank.com/drugs/DB19227InvestigationalHuman growth hormone-releasing peptide 3 is under investigation in clinical trial NCT00846872 (Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance
Tecadenoson
go.drugbank.com/drugs/DB04954InvestigationalTecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
XC221
go.drugbank.com/drugs/DB16503InvestigationalXC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.
AAV-AIPL
go.drugbank.com/drugs/DB17857ExperimentalAAV-AIPL is an adenovirus-associated viral vector serotype 8 containing the human _AIPL1_ gene. … Developed by MeiraGTx, it is being investigated for the treatment of inherited retinal dystrophy due to defects in _AIPL1_ gene.
Mosedipimod
go.drugbank.com/drugs/DB12592InvestigationalMosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
Rasburicase
go.drugbank.com/drugs/DB00049ApprovedInvestigationalRasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.
NN344
go.drugbank.com/drugs/DB05115ExperimentalNN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.
Edotecarin
go.drugbank.com/drugs/DB04882InvestigationalEdotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.